1-3 of 3
Baerbel Seyfarth, MD
Close
Sort by
Journal Articles

Rituximab Improves the Outcome of Upfront Autologous Stem Cell Transplantation in Mantle Cell Lymphoma: A Comparison of Different Strategies.

Michael Rieger, MD, Mathias Witzens-Harig, MD, Manfred Hensel, MD, Baerbel Seyfarth, MD, Maike Nickelsen, MD, Michael Kneba, MD, Norbert Schmitz, MD, Anthony D. Ho, MD, Peter Dreger, MD
Journal: Blood
Blood (2007) 110 (11): 5106.
https://doi.org/10.1182/blood.V110.11.5106.5106
Published: 2007
Journal Articles

Favorable Influence of Pretransplant Rituximab but Not of High-Dose Ara-C in Upfront Autologous Stem Cell Transplantation (SCT) for Mantle Cell Lymphoma (MCL).

Michael Rieger, MD, Manfred Hensel, MD, Baerbel Seyfarth, MD, Soeren Sitter, Simona Martin, MD, Rainer Haas, MD, Michael Kneba, MD, Norbert Schmitz, MD, Anthony D. Ho, MD, Peter Dreger, MD
Journal: Blood
Blood (2005) 106 (11): 2089.
https://doi.org/10.1182/blood.V106.11.2089.2089
Published: 2005
Journal Articles

Upfront Autologous Stem Cell Transplantation (SCT) Ameliorates the Prognostic Disadvantage of an Intermediate/High-Risk FLIPI Score in Patients with Advanced Follicular Lymphoma (FL): Evidence from Two Independent Data Sets.

Kornacker Martin, MD, Simone Suessmilch, MD, Hilde Gulla, Baerbel Seyfarth, MD, Robert Schoch, MD, Michael Kneba, MD, Anthony D. Ho, MD, Manfred Hensel, MD, Norbert Schmitz, MD, Peter Dreger, MD
Journal: Blood
Blood (2005) 106 (11): 2070.
https://doi.org/10.1182/blood.V106.11.2070.2070
Published: 2005